Last updated: 2026-09-04 19:02:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Immunic, Inc. (IMUX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $12.71, with a market capitalization of $194.30M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.06 to $17.43. This page covers its latest market performance, valuation, price trends and company information.
$194.30M | |
$12.77 | |
$289.90 | |
$5.06 | |
$12.76 | |
206.97K | |
-- | |
-- | |
$17.43 | |
$5.06 | |
-- | |
-- |
Immunic, Inc. (IMUX) is currently trading at $12.71 as of 2026-09-04 19:01:00, down 0.36% ($0.05) from the previous close of $12.76
During today's regular trading session, IMUX has traded between $5.06 and $289.90, with a trading volume of 206.97K shares. The current price is near the lower end of today's range.
Over the past seven days, Immunic, Inc. (IMUX) moved from $15.39 to $12.71, representing a decline of 17.39% ($2.68).
The stock traded between $12.49 and $12.99 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 306.90 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 61.9%
IMUX is currently trading at $12.71, placing it 61.9% of the way from its 52-week low of $5.06 to its 52-week high of $17.43. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 95 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Immunic, Inc. (IMUX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.